Literature DB >> 14727150

Empiric oral monotherapy for hospitalized patients with community-acquired pneumonia: an idea whose time has come.

B A Cunha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14727150     DOI： 10.1007/s10096-003-1061-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  22 in total

1.  Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community-acquired pneumonia.

Authors:  B A Cunha
Journal:  Am J Med       Date:  2001-10-01       Impact factor: 4.965

2.  Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial.

Authors:  A Castro-Guardiola; A L Viejo-Rodríguez; S Soler-Simon; A Armengou-Arxé; V Bisbe-Company; G Peñarroja-Matutano; J Bisbe-Company; F García-Bragado
Journal:  Am J Med       Date:  2001-10-01       Impact factor: 4.965

3.  Infectious disease outbreaks in nursing homes: an unappreciated hazard for frail elderly persons.

Authors:  Larry J Strausbaugh; Shirin R Sukumar; Carol L Joseph
Journal:  Clin Infect Dis       Date:  2003-03-19       Impact factor: 9.079

4.  Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin.

Authors:  H Fredlund; L Bodin; E Bäck; H Holmberg; A Krook; H Rydman
Journal:  Scand J Infect Dis       Date:  1987

5.  Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.

Authors:  P Petitpretz; P Arvis; M Marel; J Moita; J Urueta
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

6.  Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.

Authors:  J Ramirez; J Unowsky; G H Talbot; H Zhang; L Townsend
Journal:  Clin Ther       Date:  1999-01       Impact factor: 3.393

7.  Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil.

Authors:  J R Hendrickson; D S North
Journal:  Ann Pharmacother       Date:  1995-06       Impact factor: 3.154

8.  Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.

Authors:  F Trémolières; F de Kock; N Pluck; R Daniel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

9.  Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.

Authors:  J A Ramirez; L Srinath; S Ahkee; A Huang; M J Raff
Journal:  Arch Intern Med       Date:  1995-06-26

10.  Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial.

Authors:  R Chan; L Hemeryck; M O'Regan; L Clancy; J Feely
Journal:  BMJ       Date:  1995-05-27
View more
  3 in total

Review 1.  [Sense and nonsense in antibiotic therapy for respiratory tract infections].

Authors:  W Domej; E Flögel; G P Tilz; U Demel
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

2.  Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs).

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-18       Impact factor: 3.267

Review 3.  The atypical pneumonias: clinical diagnosis and importance.

Authors:  B A Cunha
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.